Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL

TOP - February 2017, Vol 10, No 1 - Conference Correspondent

It is estimated that 18,960 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in 2016, and 4660 deaths. This type of cancer is more often in older individuals (median age, 71 years) at diagnosis than in patients age <55 years (11%) in the United States. The median survival in patients with CLL ranges from 2 years to >10 years. The first-line standard of care for patients with CLL without deletion (del)17p is a combination chemotherapy with the regimen of fludarabine, cyclophosphamide, and rituximab (FCR) or with the regimen of bendamustine plus rituximab (BR).

An analysis of administrative claims from the Truven Health MarketScan Research database was used to examine differences in healthcare utilization between 2 cohorts of newly diagnosed patients with CLL who received treatment either with BR or FCR. In addition, the investigators analyzed differences across age-groups.

A total of 1795 patients with newly diagnosed CLL were identified who received treatment with first-line BR (N = 946) or with FCR (N = 849). Patients in the BR cohort were significantly older, included more women, and more often had comorbidities compared with the patients who received treatment with the FCR regimen (P <.05 for all differences).

The patients who received the BR regimen had significantly fewer outpatient visits than the patients in the FCR cohort during the first 6 months of therapy, as well as during months 12 to 18 (14.05 vs 17.03, respectively); across all follow-up periods, the patients in the BR cohort were also less likely to have a visit to the emergency department or to be hospitalized (odds ratio [OR], 0.66; P <.05).

Some differences were especially clear between the 2 cohorts. The patients in the FCR cohort who were older (age ≥70 years), had, on average, more outpatient visits (OR for emergency department visit, 1.14), and a greater likelihood of an emergency department visit or a hospitalization stay (OR for hospitalization, 1.50) than the patients in the BR cohort.

Overall, these results suggest that the healthcare utilization among patients with CLL who continue to use the BR regimen is significantly lower than the healthcare utilization of patients who use the FCR regimen long-term. Furthermore, patients aged ≥70 years who received treatment with the FCR regimen had significantly more hospitalizations, outpatient visits, and visits to the emergency department than those who received treatment with the BR regimen.

These results support the use of BR as an effective and safe chemoimmunotherapy option for elderly patients with CLL in the era of novel agents and immunotherapies.

Related Items
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Chemotherapy Treatment Considerations in Special Patient Populations
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Updated NCCN Guidelines for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
Wayne Kuznar
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, NCCN News, NCCN
Last modified: April 27, 2020